Condition: Small-cell Lung Cancer · Neuroendocrine Carcinomas · Solid Tumor Show to Express DLL3 · Sponsor: IDEAYA Biosciences
This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.
This description comes directly from the study's public registry record.
IDEAYA Clinical Trials · +1-855-433-2246 · IDEAYAClinicalTrials@ideayabio.com
Always discuss trial participation with your own doctor first.
| Sarah Cannon Research Institute at HealthONE | Denver, Colorado, United States | Recruiting |
| Sarah Cannon Research Institute at Florida Cancer Specialists | Orlando, Florida, United States | Recruiting |
| Fort Wayne Medical Oncology and Hematology, Inc. - Fort Wayne North Office | Fort Wayne, Indiana, United States | Recruiting |
| START Midwest | Grand Rapids, Michigan, United States | Recruiting |
| The Cancer and Hematology Centers | Grand Rapids, Michigan, United States | Recruiting |
| Columbia University Medical Center - Herbert Irving Pavilion | New York, New York, United States | Recruiting |
| Sidney Kimmel Cancer Center at Thomas Jefferson University | Philadelphia, Pennsylvania, United States | Recruiting |
| Sarah Cannon Research Institute - Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Oncology Consultants, PA- Houston | Houston, Texas, United States | Recruiting |
| Next Oncology Dallas | Irving, Texas, United States | Recruiting |
| NEXT Oncology Virginia | Fairfax, Virginia, United States | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07174583